Overview
- Medtronic topped Wall Street estimates in its fourth quarter with revenue gains led by Cardiac Ablation Solutions, which grew 78% globally and 124% in the U.S., lifting U.S. market share by eight points.
- The company set fiscal 2027 targets for 6.75%–7.25% organic revenue growth and $5.90–$6.00 adjusted EPS, a revenue outlook that is solid but an EPS range that is modest versus some analyst expectations.
- Medtronic raised its quarterly dividend to $0.72 per share to be paid in June, signaling steady shareholder income even as it commits cash to buybacks and reinvestment.
- Analysts have trimmed price targets since the early‑June report—Bernstein cut its target to $97 and BofA to $95 while keeping positive ratings, and Goldman maintained a Hold—reflecting concern that utilization trends, tariff costs and higher reinvestment will curb near‑term margins.
- Management’s mix of tuck‑in acquisitions, product filings and higher R&D and go‑to‑market spending supports long‑term device demand but increases short‑term cost pressure, leaving investors to weigh durable procedure demand against constrained earnings expansion.